Navigation Links
Study shows new treatment strategy effective for certain lung cancers
Date:3/10/2011

New Orleans, LA LSU oncologist Vince D. Cataldo, MD, is the lead author of a review article reporting two chemotherapy drugs now indicated for second and third-line therapy in patients with advanced non-small-cell lung cancer are remarkably effective in treating a certain subset of these patients. Dr. Cataldo, a Clinical Assistant Professor of Medicine at LSU Health Sciences Center New Orleans School of Medicine, practicing at LSU's Earl K. Long Medical Center and Hematology-Oncology Clinic in Baton Rouge, and his colleagues say these drugs should be considered as a first-line treatment in people who are known to carry an Epidermal Growth Factor Receptor (EGFR) mutation. The paper is published in the March 10, 2011 issue of the New England Journal of Medicine.

The drugs, Erlotinib and Gefitinib, which are in a class of highly-specific small molecule tyrosine kinase inhibitors, work by blocking the activation of EGFR which is involved in cell survival and growth, as well as the development of a nourishing blood supply and metastasis.

"Targeting the genetic mutation contributing to the development of the cancer, this class of drugs produced a response rate that exceeded 70% in these patients," notes Dr. Cataldo.

The drugs, taken by mouth, also had fewer side effects. Unlike traditional cytotoxic agents, Erlotinib and Gefitinib do not typically cause myelosuppression, neuropathy, alopecia, or severe nausea.

Lung cancer, the leading cause of cancer-related death worldwide, accounted for an estimated 157,300 deaths in the United States in 2010. Approximately 85 to 90% of all cases of lung cancer are nonsmall-cell lung cancer (NSCLC) which is also associated with smoking. Advanced-stage NSCLC is currently considered an incurable disease for which standard chemotherapy provides marginal improvement in overall survival at the expense of substantial morbidity and mortality. Furthermore, less than 30% of patients with metastatic NSCLC have a response to platinum-based chemotherapy, the most commonly used initial treatment in this stage of the disease. Even with the addition of newer agents, such as bevacizumab, to chemotherapy, the median overall survival of patients with metastatic NSCLC remains approximately 1 year, and only 3.5% of patients with metastatic NSCLC survive 5 years after diagnosis.

"The EGFR mutation is just one of the mutations associated with non-small-cell lung cancer," says Dr. Cataldo. "These results also provide a model for identifying others, which we are currently pursuing. Treatment targeting the causes of this cancer will not only improve quality of life, but may also improve survival of this devastating disease."

The University of Texas the University of Texas M.D. Anderson Cancer Center, and Montefiore Medical Center, Albert Einstein College of Medicine also participated in the review.


'/>"/>

Contact: Leslie Capo
lcapo@lsuhsc.edu
504-568-4806
Louisiana State University Health Sciences Center
Source:Eurekalert

Related biology news :

1. Study finds usage of, recommendations for supplements common within various physician specialties
2. Study provides explanation for connection between low birth weight and obesity later in life
3. New UF study shows some sharks follow mental map to navigate seas
4. Study shows how plants sort and eliminate genes over millennia
5. MBARI and Monterey Bay National Marine Sanctuary to study effects of shipping containers lost at sea
6. Rensselaer professor utilizing New York state grant to study adult stem cells
7. Study analyzes role of PARP enzyme in eukaryotes
8. Fossil bird study describes ripple effect of extinction in animal kingdom
9. University of Missouri researcher study provides insight into how corn makes hormones
10. Rainwater harvest study finds roofing material affects water quality
11. A study reveals the keys to the locomotion of snails
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2017)... ITHACA, N.Y. , June 23, 2017 ... a leader in dairy research, today announced a new ... help reduce the chances that the global milk supply ... this dairy project, Cornell University has become the newest ... Food Supply Chain, a food safety initiative that includes ...
(Date:6/14/2017)... IBM ) is introducing several innovative partner startups at ... between startups and global businesses, taking place in ... startups will showcase the solutions they have built with IBM ... France is one of the most ... increase in the number of startups created between 2012 and ...
(Date:5/23/2017)... , May 23, 2017  Hunova, the first robotic gym for the ... been officially launched in Genoa, Italy . The first ... and the USA . The technology was developed ... market by the IIT spin-off Movendo Technology thanks to a 10 million ... News Release, please click: ...
Breaking Biology News(10 mins):
(Date:6/20/2017)... , ... June 20, 2017 , ... Do More with ... transition from being a trusted supplier in the weighing industry, to extending its expertise ... ELISA essays, enzyme reactions, immunoassays, hybridizations and more, allowing for its customers ...
(Date:6/19/2017)... PA (PRWEB) , ... June 19, 2017 , ... ... companies for over 50 years. One of the biggest challenges faced by life sciences, ... firm’s regulatory affairs services team is Kati Abraham , who is well known ...
(Date:6/16/2017)... ... ... CTNext , Connecticut’s go-to resource for entrepreneurial support, today announced the ... Piers in Stamford. , Nine finalists, all of whom are Connecticut-based companies and entrepreneurs, ... secure $10,000 awards to help support business growth. The winners included:, ...
(Date:6/15/2017)... ... June 15, 2017 , ... ... new medical device startup. Dan Parsley, angelMD’s SVP of Corporate Development, served as ... this angelMD syndicate is part of Saranas’ recently announced $4 million Series B ...
Breaking Biology Technology: